Teva agrees to buy Allergan's generics distribution unit
Teva Pharmaceuticals considers laying-off 10,000 workers - The Jerusalem Post
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Roche's Ocrevus achieves blockbuster status - Pharmaceutical Technology
Teva Pharmaceutical Stock Could Double | Barron's
Teva Pharmaceutical Industries Ltd. | BioWorld
Teva files potential blockbuster migraine drug for FDA approval
Cramer: Avoid This Drug Stock
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva, the world's largest generic drugmaker, is cutting 14,000 workers - Los Angeles Times
Silver Spring-based United Therapeutics settles patent dispute over Remodulin generic with Teva Pharmaceuticals - Washington Business Journal
Teva to cut 14,000 jobs | Business | Chemistry World
In opioid case, NY wants to probe Teva's control of Teva USA
Teva bullish ahead of 2-step biosimilar attack on AbbVie's blockbuster Humira
Why Teva Pharmaceutical Is Substantially More (NYSE:TEVA) | Seeking Alpha
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva banks on blockbuster Austedo sales as COVID-19, Copaxone generics take their toll | Fierce Pharma
Generics distributor Anda, Inc. has a new owner: Teva Pharma
Teva seeks blockbuster drug to succeed Copaxone - Globes
Teva buys Allergan: 3 reasons why it's a blockbuster deal | Fortune
Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) | Seeking Alpha
Generic-drug maker Teva steals market share from Big Pharma - Aug. 5, 2009
Teva: Definitely Undervalued (NYSE:TEVA) | Seeking Alpha
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
